Neurostimulation devices market seen reaching $14.6B by 2031

The global neurostimulation devices market is projected to grow from $6.7 billion in 2024 to $14.6 billion by 2031, driven by rising neurological disease rates, broader use of minimally invasive therapies and improving device technology. North America remains the largest market as hospitals and specialty clinics keep driving adoption.

Why it matters: - Neurostimulation devices are moving deeper into routine care for chronic pain, neurological disorders, movement disorders and psychiatric conditions. - The market’s projected climb to $14.6 billion by 2031 signals sustained demand for minimally invasive alternatives that can reduce reliance on long-term medication. - Expanding use could broaden treatment options for patients with conditions such as Parkinson’s disease, epilepsy, chronic pain, depression and essential tremor.

What happened: - The neurostimulation devices market is estimated to rise from $6.7 billion in 2024 to $14.6 billion by 2031. - The market is projected to grow at an 11.7% compound annual growth rate from 2024 to 2031. - Persistence Market Research released the forecast on Aug. 6, 2026. - North America leads the global market.

The details: - Implantable neurostimulation devices remain the largest product segment because of long-term therapeutic effectiveness. - Hospitals and specialty clinics are the dominant end users because they offer advanced treatment capabilities. - Market segments include spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electrical stimulation and other neurostimulation technologies. - Hospitals lead end-user demand because they combine comprehensive neurological care, skilled staff and advanced diagnostic tools. - Specialty clinics are gaining traction as more patients seek focused neurological treatment. - Ambulatory surgical centers are benefiting from preference for minimally invasive outpatient procedures. - Research institutions support development through clinical studies on new neurostimulation uses. - Device upgrades are centered on battery life, programming, wireless connectivity and MRI compatibility. - Manufacturers are also introducing smaller implantable devices, better battery performance, enhanced programming and remote monitoring. - The report links market growth to rising prevalence of neurological disease, demand for minimally invasive procedures, favorable reimbursement in several countries and broader clinical adoption. - Key companies named in the market include Boston Scientific, Medtronic, Abbott, LivaNova, Nevro, Mainstay Medical, Inspire Medical Systems, Aleva Neurotherapeutics, NeuroPace and Synapse Biomedical. - The report provides a free sample, customization options and full-report purchase links: free sample, customization request and full report.

Between the lines: - The forecast reflects a broader shift toward treatments that are more targeted and less dependent on systemic drugs. - Strong demand in North America suggests that reimbursement, infrastructure and physician awareness still matter as much as technology in driving adoption. - Clinical expansion beyond traditional neurological uses could materially widen the market if ongoing studies produce consistent results.

What's next: - Growth is likely to be shaped by continued device miniaturization, better battery life, wireless features and more personalized therapy. - Emerging uses in mental health, rehabilitation, migraine, obesity and other chronic conditions could add new demand if clinical evidence holds up. - Manufacturers may find additional growth in emerging markets as healthcare systems expand infrastructure, coverage and physician training. - Artificial intelligence integration and remote patient monitoring are likely to become more important in future product development.

The bottom line: - Neurostimulation is shifting from a niche therapy to a broader platform for chronic disease management, and market growth is expected to stay strong through 2031.